Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory ...

Allergy shots and drops offer a transformative solution for millions. Major health organisations globally endorse this ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

The FDA has approved berotralstat oral pellets for prophylactic use in patients aged 2 to than 12 years with hereditary ...

They found that an injected antibody called tezepelumab allowed 90% of people with severe asthma to reduce their use of daily ...

Major advancements in pulmonary fibrosis treatment and critical warnings regarding both indoor air quality and scientific ...

Objective Systemic corticosteroids for 5–7 days are standard care for asthma exacerbations, but the optimal duration and ...

A monthly injection for managing severe asthma could help patients safely reduce or even discontinue daily steroid ...

FeNO testing is increasingly recognized as a key first step in asthma assessment under the updated UK guidelines.

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...